NEW YORK and LONDON, September 27, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a biopharmaceutical company …
Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
NEW YORK and LONDON, September 25, 2018 - Akari Therapeutics, Plc (NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on the …
Akari Announces Second Quarter 2018 Financial Results and Business Highlights
Announced Securities Purchase Agreement For Up To $20 Million with Aspire Capital Fund, LLC NEW YORK and LONDON, September 27, 2018 - Akari Therapeutics, Plc …
[Read more...] about Akari Announces Second Quarter 2018 Financial Results and Business Highlights
Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversin’s bifunctional activity inhibiting both the Complement and Leukotriene Inflammatory Pathways
Combined inhibition of LTB4 and C5 by Coversin showed reversal of disease symptoms in preclinical rheumatoid arthritis (RA) model Ex vivo data from bullous …
Notice of Annual Shareholders Meeting & Proxy Form
Notice of Annual Shareholders Meeting 2018 Proxy Form Dear Shareholders of Akari Therapeutics, Plc: You are cordially invited to attend (and …
[Read more...] about Notice of Annual Shareholders Meeting & Proxy Form
